Patents
Literature
1 results about "3T3 cells" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
3T3 cells come from a cell line established in 1962 by two scientists then at the Department of Pathology in the New York University School of Medicine, George Todaro and Howard Green. The 3T3 cell line has become the standard fibroblast cell line. Todaro and Green originally obtained their 3T3 cells from Swiss albino mouse embryo tissue.
Use of a drug for suppressing fibrosis of silicosis
PendingCN122320971APulmonary interstitiumTetrandrine
This invention provides an application of a drug to inhibit silicosis fibrosis. This invention demonstrates that rhodioloside can inhibit the expression levels of fibrosis-related proteins Collagen 1 and α-SMA in SiO2-exposed mice, reduce the number of diffuse high-density shadows and characteristic silicotic nodules in the interstitial lung fields, and decrease the area of diffuse collagen fiber deposition. Simultaneously, rhodioloside can also inhibit TGF-β-induced expression levels of Collagen 1 and α-SMA in NIH / 3T3 cells, inhibiting the transdifferentiation of fibroblasts into myofibroblasts. Furthermore, the research results show that the effect of the same dose of rhodioloside is comparable to, or even superior to, the current first-line clinical drug for alleviating silicosis fibrosis, tetrandrine. These research results prove that rhodioloside can effectively alleviate silicosis fibrosis.
Owner:NORTH CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY